<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 10-K/A-1
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1999 Commission File No. 0-10736
- ----------------------------------- -----------------------------------
MGI PHARMA, INC.
(Exact name of Registrant as specified in its charter)
Minnesota 41-1364647
- ----------------------------------- -----------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
6300 West Old Shakopee Road, Suite
110 Bloomington, Minnesota 55343
- ----------------------------------- -----------------------------------
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code: 952/346-4700
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.01
par value
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [_]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
The aggregate market value of voting stock held by non-affiliates of the
Registrant as of March 14, 2000 was approximately $591,568,028 (based on the
closing price of such stock as reported by The Nasdaq Stock Market on such
date).
The number of shares outstanding of each of the Registrant's classes of
common stock, as of March 14, 2000, was: Common Stock, $.01 par value;
15,381,092 shares.
DOCUMENTS INCORPORATED BY REFERENCE
Pursuant to General Instruction G, the responses to Items 5, 6, 7, 7A and
8 of Part II of this report are incorporated herein by reference to certain
information contained in the Registrant's Annual Report to Shareholders for the
fiscal year ended December 31, 1999 and the responses to Items 10, 11, 12 and
13 of Part III of this report are incorporated herein by reference to certain
information contained in the Registrant's definitive Proxy Statement for its
2000 Annual Meeting of Shareholders to be held on May 9, 2000.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
AMENDMENT NO. 1 TO FORM 10-K
This Amendment No. 1 on Form 10-K/A is being filed to correct the omission on
the cover page of Form 10-K, filed March 24, 2000, of the aggregate market
value of voting stock held by non-affiliates of the Registrant.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this Form 10-K/A-1 to be signed on
its behalf by the undersigned, thereunto duly authorized.
Dated: March 31, 2000 MGI PHARMA, INC.
By _____ /s/ Charles N. Blitzer______
Charles N. Blitzer President and
Chief Executive Officer
